Navigation Links
Schering-Plough Reports Financial Results for 2009 Second Quarter
Date:7/21/2009

merger and acquisition-related items and other specified items $136 $307 $305 $893 ==== ==== ==== ==== (a) Included in cost of sales (b) Included in cost of sales, selling, general and administrative and research and development (c) Included in other expense (income), net (d) Included in special, merger and acquisition-related charges (e) Included in research and development (f) Included in equity income 

    SCHERING-PLOUGH CORPORATION

    Report for the period ended June 30 (unaudited):

    GAAP Net Sales by Key Product

    (Dollars in millions)         Second Quarter            Six Months
                                  --------------            ----------
                                   2009   2008      %     2009    2008    %
                                   ----   ----      -     ----    ----    -

    PRESCRIPTION PHARMACEUTICALS $3,589 $3,702     (3%) $6,968  $7,259   (4%)
       REMICADE                     565    557       2%  1,083   1,064     2%
       NASONEX                      321    311       3%    627     618     1%
       TEMODAR                      256    251       2%    503     487     3%
       PEGINTRON                    215    229     (6%)    430     454   (5%)
       CLARINEX / AERIUS            226    240     (6%)    400     454  (12%)
       FOLLISTIM / PUREGON          145    162    (11%)    275     308  (10%)
       NUVARING                     129    116      11%    244     212    15%
       CLARITIN Rx                   96    111    (13%)    228     239   (4%)
       AVELOX                        71     67       7%    180     209  (14%)
       INTEGRILIN                    73     78     (7%)    149     152   (2%)
       REBETOL                       67     70     (4%)    134     130     3%
       CAELYX                        68   
'/>"/>
SOURCE  Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... -- Marrone Bio Innovations (MBI) today announces 2 ... Chris Hildreth joined MBI as Senior Vice President ... all commercial aspects of the company, including sales, ... (Ray) Lam joined MBI as Vice President of ... in scaling its broad pipeline of products to ...
(Date:12/10/2009)... N.C., Dec. 10 Microban International, ... product protection, has partnered with Sharp Imaging ... of Sharp Electronics, to incorporate it,s third ... printing calculators. Infused into the calculator keys ... inhibits the growth of damaging bacteria on ...
(Date:12/10/2009)... 10 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: ... product development company that identifies and advances a ... stages of development, today provided an update on ... merger of Cytopia Ltd. into YM, details of ... board of directors of Cytopia has unanimously recommended ...
(Date:12/10/2009)... Biomatrica, the leader in room temperature ... SampleWare 3.1 software system for laboratory inventory, organization ... now includes an audit trail functionality that tracks ... complete history of any stored sample. ,, ... customers a much needed ability to track all ...
Breaking Biology Technology:Marrone Bio Innovations Announces Two New Executive Appointments 2Marrone Bio Innovations Announces Two New Executive Appointments 3Microban Signs Exclusive Agreement with Sharp Electronics to Launch Calculators with New Microban(R) 3G Silver(TM) Antimicrobial Technology 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 3YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 4Biomatrica Launches SampleWare 3.1 2Biomatrica Launches SampleWare 3.1 3
... Board: LTUS) ("Lotus" or the,"Company"), a pharmaceutical company in the ... quarter and six months,ended June 30, 2008., Second ... million, up 51.4% from the second ... up 76.4% from the second quarter of 2007, ...
... sales of $15 million in 2008 on target; Potential label ... expansion could further ... (Nasdaq and MTA: CTIC) reported financial results for the quarter,ended ... million,compared to $20,000 for the second quarter of 2007 due ...
... --- For more than 15 years, carbon nanotubes ... Researchers have conceived applications for nanotubes ranging from ... should, in theory, give them mechanical and electrical ... , Unfortunately, theory and experiments have failed to ...
Other Biology Technology:Lotus Pharmaceuticals Announces Second Quarter 2008 Results 2Lotus Pharmaceuticals Announces Second Quarter 2008 Results 3Lotus Pharmaceuticals Announces Second Quarter 2008 Results 4Lotus Pharmaceuticals Announces Second Quarter 2008 Results 5Lotus Pharmaceuticals Announces Second Quarter 2008 Results 6Lotus Pharmaceuticals Announces Second Quarter 2008 Results 7Lotus Pharmaceuticals Announces Second Quarter 2008 Results 8Lotus Pharmaceuticals Announces Second Quarter 2008 Results 9Lotus Pharmaceuticals Announces Second Quarter 2008 Results 10Lotus Pharmaceuticals Announces Second Quarter 2008 Results 11Lotus Pharmaceuticals Announces Second Quarter 2008 Results 12Lotus Pharmaceuticals Announces Second Quarter 2008 Results 13Lotus Pharmaceuticals Announces Second Quarter 2008 Results 14Lotus Pharmaceuticals Announces Second Quarter 2008 Results 15Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results 2Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results 3Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results 4Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results 5Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results 6Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results 7True properties of carbon nanotubes measured 2True properties of carbon nanotubes measured 3
(Date:12/11/2009)... granted an 18-month, exclusive option to startup Thermalin ... The company must reach certain milestones in order ... license on therapies designed to help patients with ... that it hopes will become an important part ... Insulin is a therapeutic protein used to manage ...
(Date:12/11/2009)... discoveries about the deep ocean,s temperature variability and circulation ... , The deep ocean is affected more by surface ... more accurate predictions of factors such as sea level ... temperatures have also been found to result in a ... in a faster transport of large quantities of warm ...
(Date:12/11/2009)... CORVALIS, ORFruit growers, profits have traditionally been ... climates where growing seasons can be short. ... developed varieties are being introduced that offer ... the offseasonresulting in economic bonuses for both ... new varieties of blackberry called "primocane-fruiting", which ...
Breaking Biology News(10 mins):Case Western Reserve University grants option to startup Thermalin Diabetes Inc. 2New discoveries could improve climate projections 2New management methods extend blackberry season 2Hedgehog pathway may hold key to anti cancer therapy 55453 1Hedgehog pathway may hold key to anti cancer therapy 55453 2HCA Kicks Off 2009 Caring for the Community Campaign 55451 1HCA Kicks Off 2009 Caring for the Community Campaign 55451 2HIMSS Electronic Health Record Association Applauds Federal Support of EHR Implementation for Hospitals and Physician Practices 55449 1HIMSS Electronic Health Record Association Applauds Federal Support of EHR Implementation for Hospitals and Physician Practices 55449 2HIMSS Electronic Health Record Association Applauds Federal Support of EHR Implementation for Hospitals and Physician Practices 55449 3
... Mutations in two genes that control electrical excitability in ... a human-like insomnia disorder in mice, UT Southwestern Medical ... better understand the disorder and provide an animal model ... the most dramatic sleep-disturbance mutations, said Dr. Rolf Joho, ...
... the development of new drugs, bioactive nanomaterials, ... coatings for semiconductors, coatings and adhesives for ... nanomaterials, and surface-sensitive adhesives, to name a ... from the discovery that, under proper conditions, ...
... 2008) In an epidemiological study, Tufts University researchers identified ... of the United States population based on measures ... the bloodstream. Plasma PLP is the indicator used by ... Allowance (RDA) of vitamin B6, a nutrient essential for ...
Other Biology News:Gene mutations in mice mimic human-like sleep disorder, UT Southwestern researchers find 2Scripps Research Institute awarded patent for remarkable chemical technology 2Scripps Research Institute awarded patent for remarkable chemical technology 3Scripps Research Institute awarded patent for remarkable chemical technology 4Study identifies trends of vitamin B6 status in US population sample 2Study identifies trends of vitamin B6 status in US population sample 3
Bovine Coronary Artery Smooth Muscle Cells (BCASMC) (>500,000 cells)...
Bovine Pulmonary Artery Endothelial Cells (BPAEC) (>500,000 cells)...
Bovine Aortic Smooth Muscle Cells (BAOSMC) (>500,000 cells)...
Bovine Brain Microvascular Endothelial Cells (BBMVEC) (>500,000 cells)...
Biology Products: